AI Engines For more Details: Perplexity Kagi Labs You
Gastrointestinal Conditions: Clidinium bromide is commonly prescribed for the management of gastrointestinal disorders such as peptic ulcers, gastritis, irritable bowel syndrome (IBS), and functional dyspepsia. It works by reducing gastrointestinal spasms and motility, thereby relieving symptoms such as abdominal pain, cramping, bloating, and discomfort.
Peptic Ulcers: Clidinium bromide may be used as part of combination therapy for the treatment of peptic ulcers, which are sores that develop on the lining of the stomach, small intestine, or esophagus due to excessive stomach acid production or infection with Helicobacter pylori bacteria. By reducing stomach acid secretion and inhibiting gastrointestinal motility, clidinium bromide helps to promote ulcer healing and alleviate symptoms associated with peptic ulcers, such as abdominal pain and indigestion.
Irritable Bowel Syndrome (IBS): Clidinium bromide is also used in the management of irritable bowel syndrome (IBS), a chronic gastrointestinal disorder characterized by abdominal pain, bloating, diarrhea, and/or constipation. It helps to reduce gastrointestinal spasms and normalize bowel function, thereby relieving symptoms and improving quality of life in individuals with IBS.
Functional Dyspepsia: Clidinium bromide may be prescribed for the treatment of functional dyspepsia, a condition characterized by recurrent or persistent upper abdominal pain or discomfort without evidence of organic disease. It helps to alleviate symptoms such as early satiety, bloating, nausea, and belching by reducing gastrointestinal motility and promoting gastric emptying.
Safety Concerns: Clidinium bromide may cause certain side effects, including dry mouth, blurred vision, constipation, urinary retention, and cognitive impairment (such as confusion, dizziness, or drowsiness). These side effects are more common in elderly patients and may be exacerbated by factors such as dehydration, concurrent use of other medications with anticholinergic effects, and underlying medical conditions affecting cognition or urinary function.
Contraindications: Clidinium bromide is contraindicated in individuals with a history of hypersensitivity to anticholinergic medications or any of its components, as well as in patients with narrow-angle glaucoma, obstructive urinary disorders, severe ulcerative colitis, myasthenia gravis, or toxic megacolon. It should be used with caution in elderly patients and those with conditions predisposing to urinary retention or cognitive impairment.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bifidobacterium longum | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.1 | -0.1 | |
| ADHD | 0.3 | 0.1 | 2 |
| Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.1 | |
| Allergic Rhinitis (Hay Fever) | 0.2 | -0.2 | |
| Allergies | 0.3 | 0.3 | |
| Allergy to milk products | 0.1 | -0.1 | |
| Alopecia (Hair Loss) | 0.1 | 0.1 | |
| Alzheimer's disease | 0.1 | 0.9 | -8 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.2 | 0.2 | |
| Ankylosing spondylitis | 0.1 | 0.1 | |
| Anorexia Nervosa | 0.2 | -0.2 | |
| Asthma | 0.1 | 0.1 | 0 |
| Atherosclerosis | 0.1 | 0.1 | 0 |
| Atrial fibrillation | 0.2 | 0.1 | 1 |
| Autism | 0.6 | 0.5 | 0.2 |
| Bipolar Disorder | 0.2 | -0.2 | |
| Brain Trauma | 0.1 | 0.1 | 0 |
| Carcinoma | 0.2 | 0.2 | 0 |
| Celiac Disease | 0 | 0.3 | 0 |
| Cerebral Palsy | 0.1 | 0.2 | -1 |
| Chronic Fatigue Syndrome | 0.2 | 0.5 | -1.5 |
| Chronic Kidney Disease | 0.3 | 0.2 | 0.5 |
| Chronic Lyme | 0.1 | -0.1 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.2 | -0.2 | |
| Coagulation / Micro clot triggering bacteria | 0.2 | -0.2 | |
| Colorectal Cancer | 0.2 | 0.1 | 1 |
| Constipation | 0.2 | -0.2 | |
| Coronary artery disease | 0.2 | -0.2 | |
| COVID-19 | 0.8 | 0.9 | -0.13 |
| Crohn's Disease | 0.4 | 0.4 | 0 |
| cystic fibrosis | 0.2 | -0.2 | |
| deep vein thrombosis | 0.1 | -0.1 | |
| Depression | 0.7 | 0.6 | 0.17 |
| Dermatomyositis | 0.1 | -0.1 | |
| Eczema | 0.1 | -0.1 | |
| Endometriosis | 0.2 | 0 | 0 |
| Epilepsy | 0.1 | 0.1 | 0 |
| Fibromyalgia | 0.5 | 0.2 | 1.5 |
| Functional constipation / chronic idiopathic constipation | 0.2 | 0.6 | -2 |
| gallstone disease (gsd) | 0.1 | 0.2 | -1 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | -0.2 | |
| Generalized anxiety disorder | 0.1 | 0.3 | -2 |
| Gout | 0.1 | -0.1 | |
| Graves' disease | 0.1 | 0.2 | -1 |
| Hashimoto's thyroiditis | 0.6 | 0.1 | 5 |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.2 | 0.2 | 0 |
| hypercholesterolemia (High Cholesterol) | 0 | 0 | |
| hyperglycemia | 0.1 | -0.1 | |
| Hyperlipidemia (High Blood Fats) | 0.1 | 0.1 | |
| hypersomnia | 0.1 | -0.1 | |
| hypertension (High Blood Pressure | 0.1 | 0.6 | -5 |
| Hypothyroidism | 0.2 | -0.2 | |
| IgA nephropathy (IgAN) | 0.1 | -0.1 | |
| Inflammatory Bowel Disease | 0.4 | 0.5 | -0.25 |
| Insomnia | 0.1 | 0.1 | 0 |
| Intelligence | 0.1 | 0.1 | |
| Intracranial aneurysms | 0.1 | 0.1 | |
| Irritable Bowel Syndrome | 0.2 | 0.2 | 0 |
| Liver Cirrhosis | 0.4 | 0.3 | 0.33 |
| Long COVID | 0.7 | 0.6 | 0.17 |
| Low bone mineral density | 0.2 | -0.2 | |
| Lung Cancer | 0.1 | -0.1 | |
| ME/CFS with IBS | 0.4 | -0.4 | |
| ME/CFS without IBS | 0.1 | 0.1 | 0 |
| Menopause | 0.1 | 0.1 | |
| Metabolic Syndrome | 0.4 | 0.7 | -0.75 |
| Mood Disorders | 0.8 | 0.6 | 0.33 |
| multiple chemical sensitivity [MCS] | 0.1 | -0.1 | |
| Multiple Sclerosis | 0.3 | 0.1 | 2 |
| Multiple system atrophy (MSA) | 0.2 | 0.1 | 1 |
| Neuropathy (all types) | 0.1 | 0.1 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0 | 0 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.1 | 0.5 | -4 |
| NonCeliac Gluten Sensitivity | 0.1 | -0.1 | |
| Obesity | 0.9 | 0.2 | 3.5 |
| obsessive-compulsive disorder | 0.2 | 0.6 | -2 |
| Osteoarthritis | 0.3 | 0.3 | |
| Osteoporosis | 0.1 | -0.1 | |
| pancreatic cancer | 0 | 0 | |
| Parkinson's Disease | 0.1 | 0.3 | -2 |
| Polycystic ovary syndrome | 0.1 | 0.2 | -1 |
| Postural orthostatic tachycardia syndrome | 0.1 | -0.1 | |
| Premenstrual dysphoric disorder | 0.1 | 0.1 | |
| Psoriasis | 0.1 | 0.2 | -1 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.3 | 0.3 | 0 |
| Rosacea | 0.4 | 0.1 | 3 |
| Schizophrenia | 0.3 | 0.3 | 0 |
| scoliosis | 0.1 | 0.1 | |
| Sjögren syndrome | 0.1 | 0.1 | 0 |
| Sleep Apnea | 0.2 | 0.3 | -0.5 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.1 | -0.1 | |
| Stress / posttraumatic stress disorder | 0.2 | 0.3 | -0.5 |
| Systemic Lupus Erythematosus | 0.2 | 0.3 | -0.5 |
| Tic Disorder | 0 | 0.1 | 0 |
| Type 1 Diabetes | 0.2 | 0.1 | 1 |
| Type 2 Diabetes | 0.4 | 0.4 | 0 |
| Ulcerative colitis | 0.1 | 0.3 | -2 |
| Unhealthy Ageing | 0.4 | 0.3 | 0.33 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.